Galectin Therapeutics Q2 EPS $(0.20) Misses $(0.16) Estimate
Portfolio Pulse from Benzinga Newsdesk
Galectin Therapeutics (NASDAQ:GALT) reported a Q2 EPS of $(0.20), missing the analyst consensus estimate of $(0.16) by 25%. This represents a 33.33% increase in losses compared to $(0.15) per share from the same period last year.
August 13, 2024 | 12:03 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Galectin Therapeutics reported a Q2 EPS of $(0.20), missing the analyst consensus estimate of $(0.16) by 25%. This represents a 33.33% increase in losses compared to $(0.15) per share from the same period last year.
The significant miss on EPS estimates and the increase in losses compared to the same period last year are likely to negatively impact investor sentiment and the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100